Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676818 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1 | |
| SCHEMBL12195810 | 0.87 | ADRB2 (0.56) | ADRB2ADRB1 | |
| SCHEMBL12195812 | 0.87 | ADRB2 (0.56) | ADRB2ADRB1 | |
| SCHEMBL74054 | 0.87 | ADRB2 (0.56) | ADRB2ADRB1 | |
| SCHEMBL5247680 | 0.85 | ADRB2 (0.54) | ADRB2ADRB1THRB | |
| SCHEMBL13392152 | 0.84 | ADRB2 (0.53) | ADRB2ADRB1 | |
| Bicarbonate SCHEMBL28233771 | 0.82 | LTB4R (0.48) | ADRB2ADRB1 | |
| SCHEMBL13392150 | 0.82 | ADRB2 (0.58) | ADRB2ADRB1 | |
| SCHEMBL6681802 | 0.82 | L3MBTL1 (0.56) | THRATHRBALOX5PTGS2CSNK1A1 | |
| SCHEMBL10701443 | 0.82 | L3MBTL1 (0.56) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9493505-B2 | Macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | MALLINCKRODT LLC | 2015-05-28 | — | — | US | disclosed |
| US-8921521-B2 | Macrocyclic modulators of the Ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. (CA) | 2013-08-15 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-8450268-B2 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-RE42013-E1 | Macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2010-12-28 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | ADRB2 457/4885ADRB1 362/4885THRA 414/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | ADRB2 1004/4885ADRB1 554/4885THRA 77/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ADRB2 488/4885ADRB1 400/4885THRA 506/4885 |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | ADRB2 1004/4885ADRB1 554/4885THRA 77/4885 |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | ADRB2 1004/4885ADRB1 554/4885THRA 77/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | ADRB2 1004/4885ADRB1 628/4885THRA 71/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | ADRB2 457/4885ADRB1 362/4885THRA 414/4885 |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GIPR, GHRHR | ADRB2 1004/4885ADRB1 554/4885THRA 77/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | ADRB2 457/4885ADRB1 365/4885THRA 413/4885 |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | ADRB2 1004/4885ADRB1 554/4885THRA 77/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | ADRB2 1004/4885ADRB1 628/4885THRA 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.